Egide (ALGID) H2 2025 earnings summary

Executive summary

• Revenue increased 4% year-over-year to €31.3m, driven by growth at Egide SA and Egide USA, while Santier saw a significant decline in activity.

• EBITDA returned to positive territory at €0.7m, up from -€0.45m in 2024, reflecting operational improvements.

• Net loss widened to -€3.1m, mainly due to Santier's negative contribution and higher financial expenses.

• Strategic refocusing continued, including consolidation of US operations and closure of the Santier site.

• Appointment of a new Group CFO to support transformation.

Financial highlights

• Consolidated revenue: €31.34m (up 4% year-over-year).

• EBITDA: €0.70m (vs -€0.45m in 2024).

• Net profit (Group share): -€3.11m (vs -€2.37m in 2024).

• Financial expense: -€1.07m, mainly from interest and FX provisions.

• Working capital requirement improved to 36 days of revenue (from 62 days in 2024).

Outlook and guidance

• Focus remains on defense, aerospace, and high-tech applications such as thermal imaging.

• Streamlined US operations expected to improve performance after Santier closure.

• Aims to build a more resilient business model leveraging diversified portfolios.